Cereblon binding molecules in multiple myeloma

K M Kortüm; Y X Zhu; C X Shi; P Jedlowski; A K Stewart

doi:10.1016/j.blre.2015.03.003

Cereblon binding molecules in multiple myeloma

Blood Rev. 2015 Sep;29(5):329-34. doi: 10.1016/j.blre.2015.03.003. Epub 2015 Mar 27.

Authors

K M Kortüm¹, Y X Zhu¹, C X Shi¹, P Jedlowski¹, A K Stewart²

Affiliations

¹ Mayo Clinic in AZ, Department of Hematology, USA.
² Mayo Clinic in AZ, Department of Hematology, USA. Electronic address: Stewart.Keith@mayo.edu.

PMID: 25843596
DOI: 10.1016/j.blre.2015.03.003

Abstract

Immunomodulation is an established treatment strategy in multiple myeloma with thalidomide and its derivatives lenalidomide and pomalidomide as its FDA approved representatives. Just recently the method of action of these cereblon binding molecules was deciphered and results from large phase 3 trials confirmed the backbone function of this drug family in various combination therapies. This review details the to-date knowledge concerning mechanism of IMiD action, clinical applications and plausible escape mechanisms in which cells may become resistant/refractory to cereblon binding molecule based treatment.

Keywords: Aiolos; Cereblon; Cereblon binding molecules; IMiDs; Ikaros; Lenalidomide; Multiple myeloma; Pomalidomide; Thalidomide.

Published by Elsevier Ltd.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adaptor Proteins, Signal Transducing
Humans
Multiple Myeloma / genetics*
Multiple Myeloma / metabolism*
Peptide Hydrolases / metabolism*
Ubiquitin-Protein Ligases

Substances

Adaptor Proteins, Signal Transducing
CRBN protein, human
Ubiquitin-Protein Ligases
Peptide Hydrolases